Gregory Pennock

An open-label, phase 2 study evaluating the efficacy and safety of the anti-IGF-1R antibody cixutumumab in patients with previously treated advanced or metastatic soft-tissue sarcoma or Ewing family of tumours

Patrick Schöffski, D. Adkins, Jean‐Yves Blay et al. · European Journal of Cancer · 2013 · 89 citations

Metastatic Soft-tissue Sarcoma, Malignant Disease, Medicine +8

Avelumab as second-line therapy for metastatic, platinum-treated urothelial carcinoma in the phase Ib JAVELIN Solid Tumor study: 2-year updated efficacy and safety analysis

Andrea B. Apolo, John Ellerton, Jeffrey R. Infante et al. · Journal for ImmunoTherapy of Cancer · 2020 · 81 citations · Full text

Phase I Trial of ALT-801, an Interleukin-2/T-Cell Receptor Fusion Protein Targeting p53 (aa264–272)/HLA-A*0201 Complex, in Patients with Advanced Malignancies

Mayer Fishman, John A. Thompson, Gregory Pennock et al. · Clinical Cancer Research · 2011 · 52 citations · Full text

A randomized phase Ib/II study evaluating the safety and efficacy of olaratumab (IMC-3G3), a human anti-platelet-derived growth factor α (PDGFRα) monoclonal antibody, with or without doxorubicin (Dox), in advanced soft tissue sarcoma (STS).

William D. Tap, Robin L. Jones, Bartosz Chmielowski et al. · Journal of Clinical Oncology · 2015 · 18 citations

Medicine, Metronomic Therapy, Immunology +15

Phase II trial of anti-IGF-IR antibody cixutumumab in patients with advanced or metastatic soft-tissue sarcoma and Ewing family of tumors.

Patrick Schöffski, Douglas R. Adkins, Jean‐Yves Blay et al. · Journal of Clinical Oncology · 2011 · 14 citations

Immunology, Immunoediting, Pathology +18